Biotech Firm Immutep Investigated for Misleading Investors After 82 Percent Stock Collapse

2026-04-27 companies

New York, Monday, 27 April 2026.
Multiple law firms are investigating Immutep after its stock plummeted 82.6 percent in March 2026, following the abrupt discontinuation of a major cancer clinical trial due to futility.

The Collapse of TACTI-004 and Market Reaction

Sydney-based biotechnology firm Immutep Limited (NASDAQ: IMMP) specializes in developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for autoimmune diseases and cancer [5]. The company’s clinical pipeline heavily featured TACTI-004, a Phase III clinical trial evaluating its lead product candidate, eftilagimod alfa, as a first-line treatment for non-small cell lung cancer (NSCLC) [5]. However, the trajectory of this flagship study came to a sudden halt on March 13, 2026 [1][4].

Optimism Preceding the Fall

The foundation of the current legal scrutiny lies in the stark contrast between the trial’s abrupt failure and the company’s prior communications to shareholders. Just weeks earlier, on January 30, 2026, Immutep filed a Form 6-K with the U.S. Securities and Exchange Commission (SEC) that painted a decidedly optimistic picture [2]. In the filing, management stated that the TACTI-004 futility analysis was “on track for the first quarter of CY2026” and explicitly cited “strong operational progress” regarding the trial [2].

Mounting Legal Scrutiny

Consequently, multiple shareholder rights law firms have mobilized to investigate potential violations of federal securities laws. The Rosen Law Firm, a prominent New York-based global investor rights litigation practice, announced its active investigation into Immutep in late April 2026 [1][4]. The firm is currently preparing a class-action lawsuit aimed at recovering financial losses for investors, operating on a contingency fee arrangement [1][4].

Current Standing and Analyst Sentiment

The fallout from the TACTI-004 discontinuation has left Immutep in a precarious financial position as it navigates the remainder of 2026. Since the start of the year, the stock has experienced a dramatic devaluation, dropping from $2.86 down to $0.5730, representing a year-to-date decline of 79.965 percent [3]. Institutional confidence appears muted, with institutions holding merely 2.32 percent of the stock and insiders holding 3.07 percent as of March 31, 2026 [3].

Sources

Securities litigation Shareholder rights